Latest Information Update: 28 Jul 2016
At a glance
- Originator New York University
- Developer Atreaon
- Class Proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors; Tumour necrosis factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tendinitis